Home > Focus Areas > COPD Connect > Post
  • Saved

3yr
Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England

Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England

Source : https://www.dovepress.com/treatment-patterns-healthcare-utilization-and-clinical-outcomes-of-pat-peer-reviewed-fulltext-article-COPD

Some patients with chronic obstructive pulmonary disease (COPD) in England are prescribed long-acting muscarinic antagonist/long-acting β 2-agonist (LAMA/LABA) dual bronchodilator therapy. Four single-inhaler LAMA/LABA medications are available in England: aclidinium bromide/formoterol fumarate, indacaterol/glycopyrronium, tiotropium bromide/olodaterol, or umeclidinium/vilanterol.

Conclusion: Patients initiating treatment with single-inhaler LAMA/LABA in primary care in England were unlikely to switch treatments in the first three months following initiation, but some may discontinue respiratory medication. Outcomes were similar across indexed treatments.

  • 3yr
    Key Points
    • Source: International Journal of Chronic Obstructive Pulmonary Disease.
    • Conclusion: “Patients initiating treatment with single-inhaler LAMA/LABA in primary care in England were unlikely to switch treatments in the first three months following initiation, but some may discontinue respiratory medication. Outcomes were similar across indexed treatments.”
    • In the current retrospective study, international researchers used EHR and administrative data to analyze outcomes of 10,991 English patients with COPD prescribed 1 to 4 single-inhaler LAMA/LABA dual therapies
    • In total, 63.3% of patients continued to take LAMA/LABA during the 3 months following the index, and greater than half remained on the treatment after 6 months. In other results, 44% of patients discontinued dual therapy by 3 months post-index, most quit respiratory medications altogether. In total, <2.5% stepped up to triple therapy, with the same small minority stepping down to LAMA or LABA monotherapy.
    • “This suggests that patients receiving a single-inhaler LAMA/LABA are unlikely to switch treatments in the first few months after initiation, but some may discontinue respiratory medication over time,” stated the authors.
    • One limitation of the current study is that the researchers relied on EHR to determine whether the prescription medication was consumed, this approach could inflate adherence.